Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$84.23 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.57M
Market Cap
$9.96B
Enterprise Value$13.47B
Total Cash (Recent Filing)$52.22M
Total Debt (Recent Filing)$10.53M
Price to Earnings (P/E)30.6
Beta0.61
Next Earnings
May 05, 2025EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding98,938,230
10 Day Avg. Volume2,094,714
30 Day Avg. Volume1,571,898
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)N/A
Price to Sales (P/S)4.74
Price to Cash Flow (P/CF)11.50
P/FCF Ratio11.50
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.80
Enterprise Value/Ebitda22.07
Forecast
1Y Price Target
$155.32Price Target Upside52.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Company RatingThe company maintains a Buy rating with a price objective of $179, highlighting its established Ingrezza franchise and potential upside from the Crenessity CAH launch and pipeline programs.
Product UptakeSurveyed physicians indicated strong uptake of Crenessity over the next 2 years, with potential to dominate the market in 2-3 years.
Sales ExpectationsBuy-side expectations for Crenessity's first-year sales are surpassing those of the sell-side, suggesting higher sales potential.
Bears Say
ExpectationsStreet expectations for Crenessity's first-year sales are considered aggressive.
Market DynamicsConcerns about Ingrezza's market dynamics are considered overblown, but they have contributed to a pullback in NBIX stock.
Sales Impact1Q sales for Ingrezza are expected to be impacted by increased commercial headwinds, including increased utilization management from payors and a slowdown in new scripts.
---
Ownership Overview
1.09% Insiders
25.55% Mutual Funds
0.64% Other Institutional Investors
43.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $9.96B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is May 05, 2025 which is in 12 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 06, 2025. The company reported $1 earnings per share for the quarter, missing the consensus estimate of $1.606 by -$0.606.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 0.62.
How many shares outstanding does Neurocrine have?
Neurocrine has 98,938,230 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1 in its last earnings report, missing expectations of $1.606. Following the earnings report the stock price went down -18.53%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$155.32 (52.66% Upside)
$155.32 (52.66% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.72%
12-Months-Change
Fundamentals
Return on Equity
14.16%
Trailing 12-Months
Asset Growth
15.53%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
---
NBIX Company Deck
---
NBIX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Neurocrine's strong performance in 2024 with record sales for INGREZZA and the successful launch of Quinicity. While there are challenges, such as increased competitive pressure and a measured launch for Quinicity, the company is taking proactive steps to address these issues. The overall sentiment is cautiously optimistic with a focus on growth and expansion in the neuroscience field.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$155.32
▲(52.66% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Intra-Cellular Therapies
―
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+7.66%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +7.66% per trade.
---